Powered by lexis nexis

Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata

May 02, 2017 - Business Wire

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of aPhase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss. CTP-543 is an orally-administered selective inhibitor of Janus kinases 1 and 2, known as JAK1 and JAK2, which are enzymes believed to be involved in this autoimmune disorder. The Phase 2a trial is design...